Remedor Biomed Overview
- Founded
-
2009
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
1
Remedor Biomed General Information
Description
Developer of a biomedical technology platform based on the combination of two naturally-occurring glycoproteins: erythropoietin (EPO) and fibronectin (FN) designed for revolutionizes complex wound treatment. The company develops a formulation, based on erythropoietin and fibronectin, for therapeutical use in tissue regeneration in the processes of wound healing and bone repair, enabling customers to safe and effective pharmaceutical solutions for wound healing.
Contact Information
Website
remedor.com
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Social/Platform Software
Primary Office
- 12, HaAvoda Street
- Nof HaGalil
- Nof HaGalil
- Israel
+972 00-000-0000
Remedor Biomed Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Accelerator/Incubator | Completed | Startup |
Remedor Biomed Patents
Remedor Biomed Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2016314611-A1 | Topical erythropoietin formulations and methods for improving wound healing with and cosmetic use of the formulations | Active | 04-Sep-2015 | 000000000 | |
| JP-2020180137-A | Topical erythropoietin formulations and methods for improving wound healing with and cosmetic use of those formulations | Pending | 04-Sep-2015 | 000000000 | |
| AU-2016314611-B2 | Topical erythropoietin formulations and methods for improving wound healing with and cosmetic use of the formulations | Active | 04-Sep-2015 | 00000000 | |
| AU-2016314611-C1 | Topical erythropoietin formulations and methods for improving wound healing with and cosmetic use of the formulations | Active | 04-Sep-2015 | 00000000 | |
| CA-3035830-A1 | Topical erythropoietin formulations and methods for improving wound healing with and cosmetic use of the formulations | Pending | 04-Sep-2015 | A61K9/06 |
Remedor Biomed Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Saher Remedor Ph.D | Founder, Chief Technology Officer & Chief Executive Officer | ||
| Nicola Downes | Chief Financial Officer |
Remedor Biomed Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Amin Fares | Self | Board Member | 000 0000 |
| Luc Teot MD | Self | Board Member | 000 0000 |
| Noaz-Bar Nir | Self | Board Member | 000 0000 |
| Omar Alwan | Self | Board Member | 000 0000 |
| Paul Liu MD | Self | Board Member | 000 0000 |
Remedor Biomed Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Remedor Biomed Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Next Generation Technology | Venture Capital | Minority | 000 0000 | 000000 0 |